MA39247B1 - 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque - Google Patents

2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque

Info

Publication number
MA39247B1
MA39247B1 MA39247A MA39247A MA39247B1 MA 39247 B1 MA39247 B1 MA 39247B1 MA 39247 A MA39247 A MA 39247A MA 39247 A MA39247 A MA 39247A MA 39247 B1 MA39247 B1 MA 39247B1
Authority
MA
Morocco
Prior art keywords
obesity
treatment
diabetes mellitus
guanidinophenyl
hyperlipidemia
Prior art date
Application number
MA39247A
Other languages
English (en)
Other versions
MA39247A1 (fr
Inventor
Minoru Sasaki
Keiko Kakegawa
Fumiaki Kikuchi
Zenichi Ikeda
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39247A1 publication Critical patent/MA39247A1/fr
Publication of MA39247B1 publication Critical patent/MA39247B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé hétérocyclique fusionné ayant une action inhibitrice de l'entéropeptidase et une utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc.. Plus particulièrement, elle concerne un composé représenté par la formule suivante (i) : dans laquelle chaque symbole est tel que défini dans la description, ou un sel de celui-ci et l'utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc..
MA39247A 2014-02-13 2015-02-12 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque MA39247B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014025944 2014-02-13
PCT/JP2015/000640 WO2015122188A1 (fr) 2014-02-13 2015-02-12 Composé hétérocyclique

Publications (2)

Publication Number Publication Date
MA39247A1 MA39247A1 (fr) 2017-11-30
MA39247B1 true MA39247B1 (fr) 2018-04-30

Family

ID=52589730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39247A MA39247B1 (fr) 2014-02-13 2015-02-12 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque

Country Status (22)

Country Link
US (2) US9428470B2 (fr)
EP (1) EP3105228B1 (fr)
JP (1) JP6458054B2 (fr)
KR (1) KR20160113299A (fr)
CN (1) CN106170487A (fr)
AR (1) AR099399A1 (fr)
AU (1) AU2015216439A1 (fr)
BR (1) BR112016018548A2 (fr)
CA (1) CA2939675A1 (fr)
CL (1) CL2016002023A1 (fr)
CR (1) CR20160368A (fr)
EA (1) EA201691624A1 (fr)
EC (1) ECSP16067163A (fr)
IL (1) IL247018A0 (fr)
MA (1) MA39247B1 (fr)
MX (1) MX2016010561A (fr)
PE (1) PE20161396A1 (fr)
PH (1) PH12016501614A1 (fr)
SG (1) SG11201606176YA (fr)
TW (1) TW201609677A (fr)
UY (1) UY35995A (fr)
WO (1) WO2015122188A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051008B (zh) 2013-03-13 2018-05-29 武田药品工业株式会社 胍基苯甲酸酯化合物
RU2728790C2 (ru) 2014-02-10 2020-07-31 Фред Хатчинсон Кансэр Рисёч Сентер Лечение сердечного приступа и ишемического повреждения соединениями галогена
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9428470B2 (en) * 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
WO2016158788A1 (fr) * 2015-03-27 2016-10-06 武田薬品工業株式会社 Composé hétérocyclique fusionné
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
BR112020008676A2 (pt) 2017-11-02 2020-10-27 Ube Industries, Ltd. composto, e, composição farmacêutica.
EP3778577B1 (fr) 2018-05-09 2023-08-30 Lg Chem, Ltd. Nouveau composé présentant une activité inhibitrice de l'entéropeptidase
AR116019A1 (es) * 2018-08-27 2021-03-25 Scohia Pharma Inc Derivados de guanidinobenzoilo como inhibidores de enteropeptidasa
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
WO2021013742A1 (fr) 2019-07-19 2021-01-28 Janssen Pharmaceutica Nv Dérivés de [1,2,4]triazolo[1,5-a]pyridinyle 5,8-disubstitués et d'imidazo[1,2-a]pyridine 5,8-disubstitués utiles en tant qu'inhibiteurs de l'entéropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CA3160144A1 (fr) * 2019-11-04 2021-07-08 Faraday Pharmaceuticals, Inc. Utilisation de composes d'iodure pour le traitement et la prevention d'une cardiotoxicite et d'une cachexie associees a une chimiotherapie
WO2021166899A1 (fr) * 2020-02-17 2021-08-26 宇部興産株式会社 Médicament contenant un inhibiteur de protéase gastrique destiné à être utilisé en association avec un mimétique d'incrétine
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
EP0673924A4 (fr) 1992-12-10 1996-04-24 Teikoku Chem Ind Co Ltd Derive d'acide proprionique.
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
EP0862562B1 (fr) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Composes de benzoxazepine, leur production et leur utilisation en tant qu'agent d'abaissement des niveaux de lipides
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
KR20000005312A (ko) 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2527691C (fr) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Compose cyclique condense
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (fr) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Derives d'acide phenylpropanoique
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1815865A4 (fr) 2004-11-08 2010-08-25 Ono Pharmaceutical Co Agent thérapeutique contre le diabète comprenant un composé inhibiteur de protéase
EP1843819A2 (fr) 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Procedes de reduction de la graisse corporelle
EP1811865B1 (fr) 2004-11-26 2008-07-16 N.V. Nutricia Aliment pour nourrisson contenant un inhibiteur de protease
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
EP1911738A4 (fr) 2005-07-29 2009-12-16 Takeda Pharmaceutical Composé de l acide phénoxyalkanoique
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20080009530A1 (en) 2005-08-10 2008-01-10 Hidenori Abe Therapeutic Agent for Diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1973405A4 (fr) 2006-01-12 2011-06-01 Merck Sharp & Dohme Derives d'hydroxyalkymarylamide
EP2743268A3 (fr) 2006-06-27 2014-10-08 Takeda Pharmaceutical Company Limited Composés cycliques condensés comme modulateurs du recepteur GPR40
EP2298772A1 (fr) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Composés hétérocycliques condenseé
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
WO2008099794A1 (fr) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Composés à cycles fusionnés utiles en tant qu'agonistes partiels de ppar-gamma
EP2149550A4 (fr) 2007-04-27 2010-08-11 Takeda Pharmaceutical Composé hétérocyclique à cinq chaînons à teneur en azote
EP2157859A4 (fr) 2007-06-19 2011-01-12 Takeda Pharmaceutical Composés d'indazole permettant d'activer la glucokinase
PT2225261E (pt) 2007-12-03 2016-06-09 Obe Therapy Biotechnology Inibidores boropeptídicos de enteropeptidase e suas utilizações no tratamento de obesidade, excesso de peso e/ou doenças associadas com um metabolismo anormal da gordura
ES2532201T3 (es) 2009-12-07 2015-03-25 Ajinomoto Co., Inc. Derivado de éster de ácido heteroarilcarboxílico
JP5959116B2 (ja) 2011-06-07 2016-08-02 Ｅａファーマ株式会社 ヘテロ環カルボン酸エステル誘導体
MX362948B (es) 2011-09-15 2019-02-27 Astellas Pharma Inc Compuesto del ácido guanidinobenzoico.
EP2800579B1 (fr) 2012-01-03 2017-08-30 Oramed Ltd. Capsules comprenant des compositions liquides contenant une combinaison d'agents thérapeutiques pour le traitement du diabète
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP4215205A1 (fr) 2013-01-03 2023-07-26 Oramed Ltd. Procédés et compositions pour le traitement de nafld, de la stéatose hépatique et de ses séquelles
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
CN105051008B (zh) 2013-03-13 2018-05-29 武田药品工业株式会社 胍基苯甲酸酯化合物
LT3010910T (lt) 2013-06-21 2020-03-10 MyoKardia, Inc. Pirimidindiono junginiai, skirti širdies ligoms
WO2015036792A1 (fr) 2013-09-16 2015-03-19 Astrazeneca Ab Nanoparticules polymères thérapeutiques et leurs procédés de fabrication et d'utilisation
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
MA39247A1 (fr) 2017-11-30
CA2939675A1 (fr) 2015-08-20
SG11201606176YA (en) 2016-08-30
PH12016501614A1 (en) 2017-02-06
ECSP16067163A (es) 2017-10-31
EP3105228A1 (fr) 2016-12-21
AU2015216439A1 (en) 2016-08-11
UY35995A (es) 2015-08-31
CL2016002023A1 (es) 2017-03-24
IL247018A0 (en) 2016-09-29
US20160347724A1 (en) 2016-12-01
PE20161396A1 (es) 2017-01-10
BR112016018548A2 (pt) 2019-01-15
KR20160113299A (ko) 2016-09-28
CN106170487A (zh) 2016-11-30
TW201609677A (zh) 2016-03-16
US10023544B2 (en) 2018-07-17
EP3105228B1 (fr) 2018-09-26
MX2016010561A (es) 2016-11-16
US9428470B2 (en) 2016-08-30
US20150225354A1 (en) 2015-08-13
CR20160368A (es) 2016-12-01
JP2017505823A (ja) 2017-02-23
EA201691624A1 (ru) 2017-05-31
AR099399A1 (es) 2016-07-20
JP6458054B2 (ja) 2019-01-23
WO2015122188A1 (fr) 2015-08-20

Similar Documents

Publication Publication Date Title
MA39247B1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque
MA39246A1 (fr) Composé hétérocyclique fusionné
MD3269370T2 (ro) Compus pirimidinic condensat nou sau sare a acestuia
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
ECSP20075270A (es) Compuestos
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
MA46337A (fr) Composé de pyridine
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA38472A1 (fr) Composé peptidique
MA34713B1 (fr) Compose bicyclique
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA40302A1 (fr) Dérivés de carbazole
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
EA201992306A1 (ru) Ингибиторы ip6k
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38358A1 (fr) Formulations de composés organiques
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA43231B1 (fr) Bloqueur des canaux sodiques
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA45855B1 (fr) Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide